Alteration of RhoA Prenylation Ameliorates Cardiac and Vascular Remodeling in Spontaneously Hypertensive Rats

Autor: Yu-Ning Chen, Zao-Xian Xu, Liang-Rong Zheng, Yun Mou, Jian Yang
Rok vydání: 2016
Předmět:
0301 basic medicine
Male
RHOA
Physiology
Farnesyl pyrophosphate
Blood Pressure
Pharmacology
Rats
Inbred WKY
lcsh:Physiology
chemistry.chemical_compound
0302 clinical medicine
Polyisoprenyl Phosphates
Fibrosis
Rats
Inbred SHR
lcsh:QD415-436
Aorta
lcsh:QP1-981
biology
ATP synthase
Alendronate
Bone Density Conservation Agents
Ventricular Remodeling
Geranyltranstransferase
Echocardiography
Cardiovascular remodeling
030220 oncology & carcinogenesis
cardiovascular system
Collagen
Sesquiterpenes
Cardiomegaly
Vascular Remodeling
lcsh:Biochemistry
03 medical and health sciences
Prenylation
Species Specificity
medicine.artery
medicine
Animals
Ventricular remodeling
Myocardium
Farnesyl pyrophosphate synthase
medicine.disease
030104 developmental biology
chemistry
Spontaneously hypertensive rats
biology.protein
rhoA GTP-Binding Protein
Geranylgeranylation of RhoA
Zdroj: Cellular Physiology and Biochemistry, Vol 39, Iss 1, Pp 229-241 (2016)
ISSN: 1421-9778
Popis: Background: In our previous study, farnesyl pyrophosphate synthase (FPPS) was shown to be increased in spontaneously hypertensive rats (SHR) and in mice with angiotensin-II induced cardiac hypertrophy. Overexpression of FPPS induced cardiac hypertrophy and fibrosis in mice, accompanied by an increase in the synthesis of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). In the present study, we investigated the mechanisms of reversing cardiovascular remodeling in SHR by inhibiting FPPS. Methods and Results: Six-week-old rats were given vehicle or an FPPS inhibitor (alendronate, 100 ug/kg/d) daily for twelve weeks by osmotic mini-pump. The results demonstrated that FPPS inhibition attenuated cardiac hypertrophy and fibrosis in SHR as shown by the heart weight to body weight ratio, echocardiographic parameters, and histological examination. In addition, FPPS inhibition attenuated aortic remodeling as shown by reduced media thickness, media cross-sectional area and collagen of the aorta as well as SBP, DBP, MBP. Furthermore, 12 weeks of alendronate treatment significantly decreased FPP and GGPP levels, RhoA activation and geranylgeranylation in the heart and aorta, all of which were significantly upregulated in SHR compared with normotensive Wistar-Kyoto rats. Conclusion: Taken together, these results indicate that chronic treatment with alendronate decreases the development of cardiac and aortic remodeling, by a pathway which involves inhibition of the geranylgeranylation and activation of RhoA.
Databáze: OpenAIRE
Externí odkaz: